NCT06363006View on ClinicalTrials.gov

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

TKI+Cardunilimab

Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience

Trial Locations (1)

100730

RECRUITING

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER